BDF
IMUX icon

Balasa Dinverno & Foltz’s Immunic IMUX Stock Holding History

Balasa Dinverno & Foltz’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-64
Closed -$176K – 244
2018
Q2 		$176K Hold
64
– – 0.03% 220
2018
Q1 		$174K Hold
64
– – 0.03% 205
2017
Q4 		$152K Buy
64
+3
+5% +$6.63K 0.02% 209
2017
Q3 		$124K Hold
61
– – 0.02% 205
2017
Q2 		$71K Buy
+61
New +$81.4K 0.01% 206

Other funds holding IMUX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Balasa Dinverno & Foltz's IMUX Position: Q3 2018 in Review

Balasa Dinverno & Foltz sold out of Immunic (IMUX) in Q3 2018, closing a stake of 64 shares — an estimated $176K sold.

Balasa Dinverno & Foltz first reported a position in IMUX in Q2 2017 and held it in 5 quarters. The position peaked at $176K in Q2 2018. 54 funds tracked by Wall St. Rank hold IMUX as of Q3 2018.

  • Balasa Dinverno & Foltz reported no remaining Immunic position as of Q3 2018 after selling out during the quarter.
  • Balasa Dinverno & Foltz sold 64 Immunic shares in Q3 2018, an estimated $176K.
  • Balasa Dinverno & Foltz first reported a position in Immunic in Q2 2017 and held it in 5 quarters.
  • Balasa Dinverno & Foltz's Immunic position peaked at $176K in Q2 2018.
  • 54 funds tracked by Wall St. Rank held Immunic as of Q3 2018.

Based on Balasa Dinverno & Foltz's 13F filing for Q3 2018, filed 24 Oct 2018.